Kim Noonan, PhD

CHIEF SCIENTIFIC OFFICER

Dr. Noonan is a scientific co-founder of several biotech companies created to commercialize her groundbreaking-research in the areas of marrow infiltrating lymphocyte (MIL) technology, myeloma-specific cancer vaccines and bi-specifics.

Along with Ivan Borrello, M.D., Dr. Noonan pioneered the use of MILs in cell therapy. This therapeutic approach is showing promise for patients with multiple myeloma and their research indicates that this type of personalized cell therapy would be beneficial in treating a variety of blood and bone marrow cancers as well as solid tumors.

Dr. Noonan received her B.S. in Microbiology and Ph.D. in Immunology from the University of Pittsburgh. She also holds an MPH from Johns Hopkins University (JHU) and joined the faculty at JHU in 2004. She is published author on many peer-reviewed papers, articles and book chapters and holds numerous patents. Dr. Noonan has served as a consulting advisor to several mid-to-large biopharma companies as well as venture capital and family office investment funds.